<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37773731</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-2300</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of international medical research</Title><ISOAbbreviation>J Int Med Res</ISOAbbreviation></Journal><ArticleTitle>Relapse of lupus nephritis induced by nivolumab in an 84-year-old patient with oral cancer: a case report.</ArticleTitle><Pagination><StartPage>3000605231202140</StartPage><MedlinePgn>3000605231202140</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">03000605231202140</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/03000605231202140</ELocationID><Abstract><AbstractText>Various immunity-related adverse events have been reported to be associated with the inhibition of programmed cell death receptor 1. We report a rare case of a relapse of lupus nephritis (LN), involving rapidly progressive glomerulonephritis, which was induced by nivolumab treatment in a patient with oral cancer. The patient had a history of systemic lupus erythematosus and underwent treatment with steroids, rituximab, and plasmapheresis. However, her renal function did not improve, and she died of multiple organ failure. To our knowledge, this is the first description of severe LN induced by nivolumab.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhou</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Dentistry, Lishui Central Hospital; Lishui Hospital of Zhejiang University; the Fifth Affiliated Hospital of Wenzhou University, Lishui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qiankun</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-9877-3911</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Lishui Central Hospital; Lishui Hospital of Zhejiang University; the Fifth Affiliated Hospital of Wenzhou University, Lishui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinbin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Dentistry, Lishui Central Hospital; Lishui Hospital of Zhejiang University; the Fifth Affiliated Hospital of Wenzhou University, Lishui, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Int Med Res</MedlineTA><NlmUniqueID>0346411</NlmUniqueID><ISSNLinking>0300-0605</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>31YO63LBSN</RegistryNumber><NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009062" MajorTopicYN="Y">Mouth Neoplasms</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nivolumab</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">multiple organ failure</Keyword><Keyword MajorTopicYN="N">programmed cell death receptor 1</Keyword><Keyword MajorTopicYN="N">pulmonary edema</Keyword><Keyword MajorTopicYN="N">recurrent oral cancer</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>15</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37773731</ArticleId><ArticleId IdType="pmc">PMC10541768</ArticleId><ArticleId IdType="doi">10.1177/03000605231202140</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016; 375: 1767&#x2013;1778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5575761</ArticleId><ArticleId IdType="pubmed">27806234</ArticleId></ArticleIdList></Reference><Reference><Citation>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 158&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">29320654</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnier JJ, Kienle G, Altman DGet al.. CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache 2013; 53: 1541&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">24266334</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris RL, Blumenschein G, Fayette Jet al.. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375: 1856&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5564292</ArticleId><ArticleId IdType="pubmed">27718784</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer JD, Burtness B, Ferris RL. Immunotherapy for head and neck cancer: recent advances and future directions. Oral Oncol 2019; 99: 104460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749717</ArticleId><ArticleId IdType="pubmed">31683169</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361: 211&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">19587352</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab N, Shah M, Lopez-Olivo MAet al.. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann Intern Med 2018; 168: 121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">29297009</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao K, McGettigan S, Elenitsas Ret al.. Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy. J Cutan Pathol 2018; 45: 74&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">29028121</ArticleId></ArticleIdList></Reference><Reference><Citation>Marano AL, Clarke JM, Morse MAet al.. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Br J Dermatol 2019; 181: 580&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">30244487</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu RC, Sebaratnam DF, Jackett Let al.. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J Dermatol 2018; 59: e152&#x2013;e154.</Citation><ArticleIdList><ArticleId IdType="pubmed">28726325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters A, Durieux V, Kolivras Aet al.. Bullous lupus under nivolumab treatment for lung cancer: a case report with systematic literature review. Anticancer Res 2019; 39: 3003&#x2013;3008.</Citation><ArticleIdList><ArticleId IdType="pubmed">31177141</ArticleId></ArticleIdList></Reference><Reference><Citation>Koda R, Watanabe H, Tsuchida Met al.. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. BMC Nephrol 2018; 19: 48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830324</ArticleId><ArticleId IdType="pubmed">29486725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>